GET DAILY SIGNALSArtivion (AORT) Q3 2026: Revenue Climbs 9% but Margin Pressure and Integration Costs Weigh In
Key Takeaways
- Artivion reported third quarter 2026 revenue of $123.8 million, up 9% on a constant currency basis and above the consensus estimate of roughly $121 million.
- Non-GAAP (adjusted) diluted EPS came in at $0.08, beating the consensus estimate of about $0.07 per share.
- On a GAAP (Generally Accepted Accounting Principles) basis, the company posted a net loss of $(0.16) per share, down from a $0.13 profit a year earlier, reflecting higher interest expense and integration costs.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) fell 8% year over year to $22.5 million, with margin declining roughly 350 basis points to 18.2%.
- Management narrowed full-year 2026 revenue guidance to $484–$492 million and adjusted EBITDA to $93–$98 million, with the NEXUS U.S. launch still targeted for January 2027.
- For more context on the company's latest developments, you can review its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- You can also explore Trending AI Robots to see how AI-driven trading strategies are approaching the current market.
Earnings Context and Why It Matters
Artivion focuses on cardiac and vascular surgery products for aortic disease, so its quarterly results provide insight into how its specialized portfolio is gaining traction. The third quarter of 2026 stands out because it comes after the U.S. FDA PMA approval for the AMDS hybrid prosthesis and the completion of the Endospan acquisition that added the NEXUS aortic arch platform. I’m watching closely to see whether these catalysts support sustained revenue growth and how the related integration and manufacturing investments affect near-term profitability. With revenue growth slowing only slightly while margins tighten, the report highlights the tension between Artivion’s longer-term growth narrative and short-term cost pressures.
Reported Results
Artivion reported third quarter 2026 total revenue of $123.8 million, a 9% increase on a constant currency basis from $113.4 million in the prior-year quarter. This came in modestly above consensus expectations of approximately $121 million. Excluding the contribution from PerClot, constant currency growth was 8%. By product line, On-X revenue grew 13%, aortic stent grafts grew 12% for the second straight quarter, tissue processing declined 0.3%, and BioGlue rose 0.1%, while the "other" category grew 93% due to PerClot contributions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On profitability, non-GAAP diluted EPS was $0.08, above the consensus estimate of about $0.07, though down from $0.16 a year ago. On a GAAP basis, the company recorded a net loss of $(0.16) per share, compared with net income of $0.13 per share in the third quarter of 2025, driven by higher interest expense and Endospan integration costs. Adjusted EBITDA declined 8% to $22.5 million, while gross margin fell to 61.4% from 65.6%, reflecting product mix and manufacturing investments in On-X and NEXUS facilities.
Market Reaction and Investor Sentiment
Artivion shares traded lower following the release, with the stock closing down in after-hours trading on November 5, 2026, as investors weighed the top-line beat against softer profitability and a moderated full-year outlook. The revenue beat and adjusted EPS outperformance were offset by the GAAP loss, an 8% decline in adjusted EBITDA, and guidance that was narrowed rather than raised. Sentiment remains focused on whether the AMDS set-sale hurdles and NEXUS launch investments represent transient friction or a longer margin headwind. Management characterized the AMDS starter-set purchasing challenges as administrative rather than clinical, pointing to rising implant volumes as evidence of underlying adoption momentum.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should monitor several themes tied to Artivion’s guidance and pipeline. Management narrowed 2026 revenue expectations to $484–$492 million and adjusted EBITDA to $93–$98 million, with the guidance still assuming minimal U.S. NEXUS revenue this year.
The most important near-term catalyst is the planned U.S. commercial launch of the NEXUS aortic arch system in January 2027. Success will depend on manufacturing capacity, inventory build, value analysis committee approvals, and surgeon training. At the same time, the completion of the PerClot supply agreement with Baxter in February 2027 is expected to create a roughly two-percentage-point revenue headwind and a four-percentage-point adjusted EBITDA headwind next year, which investors should factor into their models.
Margin trends also warrant attention. Gross margin fell to 61.4% this quarter as the company absorbed higher costs from ramping On-X and NEXUS production, and management has signaled continued investment in these facilities. Free cash flow turned negative at $(17.6) million, partly due to a $13.3 million AMDS PMA milestone payment, and the company’s net leverage ratio stood at 3.5x at quarter-end.
Finally, pipeline progress remains a key driver. The ARTIZEN trial for the Arcevo LSA device has enrolled 56 patients toward a target of 132, with full enrollment anticipated in mid-2027. How AMDS set sales convert from implants to revenue, and how quickly NEXUS ramps, will likely shape both financial performance and investor sentiment over the next several quarters.
Using AI Tools for Deeper Analysis
From what I see, tools like Tickeron’s AI Screener can be helpful when evaluating how companies like AORT stack up against peers in the medical device space. I rely on it occasionally to quickly filter for comparable names based on fundamentals, technical patterns, and performance metrics, which adds useful context beyond the earnings numbers themselves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AORT in upward trend: price rose above 50-day moving average on November 04, 2026
AORT moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on AORT as a result. In 64 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for AORT just turned positive on October 14, 2026. Looking at past instances where AORT's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +12.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where AORT advanced for three days, in 221 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
AORT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AORT entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (4.338). AORT's P/E Ratio (-506.600) is considerably lower than the industry average of (1.324). Projected Growth (PEG Ratio) (4.200) is also within normal values, averaging (11.253). Dividend Yield (0.005) settles around the average of (0.010) among similar stocks. P/S Ratio (2.603) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. AORT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AORT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of cryopreserved human tissue for vascular transplant applications
Industry MedicalNursingServices
Advertisement